TITLE: Nocturnal noninvasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study

Acronym: RESCUE REspiratory Support in COPD after acUte Exacerbation.

F. M. Struik\textsuperscript{1,2}, R.T.M. Sprooten\textsuperscript{3}, H.A.M. Kerstjens\textsuperscript{1,2}, G. Bladder\textsuperscript{1}, M. Zijnen\textsuperscript{4}, J. Asin\textsuperscript{5}, N.A.M. Cobben\textsuperscript{3}, J.M. Vonk\textsuperscript{2,6}, P.J. Wijkstra\textsuperscript{1,2}

\textsuperscript{1}Department of Pulmonology/ Center for Home Mechanical Ventilation, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
\textsuperscript{2}Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
\textsuperscript{3}Department of Respiratory Medicine/ Center of Home Mechanical Ventilation Maastricht, Maastricht University Medical Center (MUMC), Maastricht, The Netherlands.
\textsuperscript{4}Department of Intensive Care/ Center for Home Mechanical Ventilation, University Medical Centre, Erasmus MC, Rotterdam, The Netherlands.
\textsuperscript{5}Department of Pulmonology, Amphia Hospital, Breda, The Netherlands.
\textsuperscript{6}Department of Epidemiology, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands.
METHODS

Patients
Exclusion criteria were: 1) age < 18 or => 80 years; 2) significant bronchiectasis with recurrent infections; 3) significant heart failure; 4) kyphoscoliosis; 5) neuromuscular disease; 6) obstructive sleep apnea (Apnea Hypopnea Index: AHI >15 /hr); 7) current use of Continuous Positive Airway Pressure (CPAP) or Bi-level Positive Airway Pressure (BiPAP); 8) insufficient motivation for chronic ventilatory support; 9) social circumstances making chronic ventilatory support at home impossible; 10) other diagnoses limiting life expectations.

Home Mechanical Ventilation Center
In The Netherlands we have 4 legitimated and highly experienced Home Mechanical Ventilation Centers. Patients requiring chronic ventilation at home are sent in from all hospitals in the country to be established on mechanical ventilation by these centers. The nurse practitioners are allowed to establish long-term NIV also in external hospitals and deliver care at home. For this trial as a form of quality assurance, we set up a standardized protocol for establishment and NIV set up and organized a start up meeting to make sure everybody worked according to the same standard and regulations. Also, all centers worked with the same machines.

Intervention
Patients were instructed to use NIV during the night whilst asleep and, were advised to use NIV during the day/nap times if desired.

Measurements
An overnight polygraphy or Polysomnography was performed in patients with a body mass index $\geq 30 \text{ km/m}^2$, or in patients with complaints of excessive snoring, disrupted sleep or morning headache to exclude Obstructive Sleep Apnea Syndrome.

Survival, respiratory admission rates and days in hospital were checked in hospital registers and with patients general practitioner. Exacerbations at home were registered in a diary by the patient themselves.

An exacerbation was defined using a modified version of the definition of Rodriguez-Roisin, as an event in the natural course of the disease characterized by a change in the patient’s baseline dyspnoea, cough, and/or sputum that is beyond day-to-day variations, is acute in onset, and treated with antibiotics and/or prednisolone in patients with COPD.[1]

**Lung function**

Lung function measurements included routine spirometry by means of a pneumotachograph and according to ERS criteria.[2] Absolute values and % pred. according to normal values.

**Transcutaneous measurement**

Transcutaneous monitoring during the night was performed using the TOSCA[3] to measure skin-surface $\text{PO}_2$ and $\text{PCO}_2$ to provide estimates of arterial partial pressure of oxygen and carbon dioxide ($\text{PaO}_2$ and $\text{PaCO}_2$) and saturation. The device induces hyperperfusion by local heating of the skin of the earlobe and measures the partial pressure of oxygen and carbon dioxide electrochemically. The mean nocturnal Ptc$\text{CO}_2$ was measured during the night before discharge out of hospital to see if patients were adequately adjusted to NIV. Patients in the standard treatment did not receive NIV during this measurement.
Health related quality of life questionnaires

Patients completed the following questionnaires concerning health related quality of life; the Clinical COPD Questionnaire (CCQ),[4] the Chronic Respiratory Questionnaire self reported (CRQ),[5] the Maugeri Respiratory Failure Questionnaire -28 (MRF-28)[6] and the Severe Respiratory Insufficiency (SRI) questionnaire.[7] The CCQ is a self-administered, 10-item questionnaire which can be divided into three domains: symptom, functional state and mental state. Scores range from 0 to 6 with high scores indicating extremely poor health status. The CRQ (self reported) contains 20 items and measures physical function and emotional function, divided into four domains: dyspnoea, fatigue, emotion and mastery. Scores range from 1 (worse) to 7 (best). The MRF-28 contains 28 items which are divided into 3 domains; daily activity, cognitive function and invalidity. The scores range from 0 (best) to 100 (worse). The SRI contains seven domains covering 49 items: respiratory complaints, physical functioning, attendant symptoms and sleep, social relationships, anxiety, psychological well-being and social functioning. Scoring ranges between 0-100, with high scores representing better HRQL.

Other measurements

The Groningen Activity and Restriction Scale (GARS) assesses activity and disability of daily living and consists of 18 items.[8] The Hospital Anxiety and Depression Scale (HADS) was used to determine levels of depression and anxiety.[9] It consists of 14 questions from which seven are on detection of anxiety and seven on depression (two subscales). Dyspnoea was measured using the Medical Research Council scale (MRC).[10]

We could not perform the 6-minute walking test since most patients were too weak to perform this test adequately and safely, raising ethical concerns. Our alternative of measuring walking distance with a pedometer also fell short, as we noticed that in the patients who
barely walk, shuffling occurs leading to an underestimation as the pedometer does not always
detect their effort and thus real number of steps per day.

Statistical analysis

Continuous variables were summarized as means and standard deviations, or medians and
ranges depending on their distribution. Changes within groups were compared using the
paired sample T-test. Between group comparisons of continuous variables were performed
using the independent samples T-test for variables with a normal distribution or the Mann-
Whitney U test for variables with a non-normal distribution. Difference in change within
groups and treatment effect between groups are shown as means with associated 95%
confidence intervals (C.I.) and p-value (p<0.05 was considered statistically significant).
### Supplementary file Table S1: Reasons for dropping out of study

<table>
<thead>
<tr>
<th>Reason</th>
<th>NIV n=25</th>
<th>Standard treatment n=24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lack of motivation</td>
<td>15</td>
<td>14</td>
</tr>
<tr>
<td>Unable to come for testing</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Discomfort associated with treatment</td>
<td>8</td>
<td>-</td>
</tr>
<tr>
<td>Critical intercurrent illness:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Dementia</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>- CVA</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Switch to NIV</td>
<td>-</td>
<td>4</td>
</tr>
</tbody>
</table>

CVA cerebrovascular accident; n, numbers for analysis; NIV, noninvasive positive pressure ventilation.

### Supplementary file Table S2: Causes of death

<table>
<thead>
<tr>
<th>Cause</th>
<th>ITT NIV n=30</th>
<th>ITT Standard treatment n=29</th>
<th>Non-drop outs NIV n=22</th>
<th>Non-drop outs Standard treatment n=22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory causes</td>
<td>21</td>
<td>25</td>
<td>15</td>
<td>20</td>
</tr>
<tr>
<td>Natural cause</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Pneumothorax</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Cardiac disease</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Lung carcinoma</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

ITT, intention-to-treat; n, numbers for analysis; NIV, noninvasive positive pressure ventilation.
Supplementary file Table S3: Changes in the Clinical COPD Questionnaire (CCQ) sub domains

<table>
<thead>
<tr>
<th></th>
<th>ITT Baseline</th>
<th>n</th>
<th>Completers Baseline</th>
<th>n</th>
<th>Completers 12 months</th>
<th>n</th>
<th>Change over 1 year</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CCQ-Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>3.4 ± 1.2</td>
<td>96</td>
<td>3.4 ± 1.2</td>
<td>48</td>
<td>2.9 ± 1.1</td>
<td>48</td>
<td>-0.5 (-0.2; -0.8)</td>
<td>48</td>
</tr>
<tr>
<td>Controls</td>
<td>3.3 ± 1.2</td>
<td>90</td>
<td>3.2 ± 1.0</td>
<td>51</td>
<td>2.8 ± 1.1</td>
<td>51</td>
<td>-0.5 (-0.8; -0.1)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>3.1 ± 1.2</td>
<td>99</td>
<td>3.0 ± 1.2</td>
<td>51</td>
<td>2.7 ± 1.2</td>
<td>51</td>
<td>-0.3 (-0.6; 0.1)</td>
<td>51</td>
</tr>
<tr>
<td>Controls</td>
<td>3.1 ± 1.1</td>
<td>90</td>
<td>3.2 ± 1.1</td>
<td>51</td>
<td>2.8 ± 1.1</td>
<td>51</td>
<td>-0.4 (-0.7; -0.04)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td>-0.04 (-0.5; 0.4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>4.1 ± 1.4</td>
<td>99</td>
<td>4.1 ± 1.5</td>
<td>49</td>
<td>3.5 ± 1.5</td>
<td>49</td>
<td>-0.5 (-0.9; -0.2)</td>
<td>49</td>
</tr>
<tr>
<td>Controls</td>
<td>4.0 ± 1.4</td>
<td>90</td>
<td>3.9 ± 1.4</td>
<td>51</td>
<td>3.4 ± 1.4</td>
<td>51</td>
<td>-0.5 (-0.9; -0.1)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td>-0.07 (-0.6; 0.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>2.6 ± 1.8</td>
<td>96</td>
<td>2.7 ± 1.8</td>
<td>50</td>
<td>1.7 ± 1.3</td>
<td>50</td>
<td>-1.0 (-1.4; -0.6)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>2.3 ± 1.7</td>
<td>90</td>
<td>2.2 ± 1.6</td>
<td>51</td>
<td>1.6 ± 1.5</td>
<td>51</td>
<td>-0.6 (-1.0; -0.2)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td>-0.40 (-1.0; 0.2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data presented as means (± standard deviation) and mean change (95% confidence intervals).
CCQ, Clinical COPD Questionnaire; ITT, intention-to-treat; n, numbers for analysis; NIV, noninvasive positive pressure ventilation.

\(^\dagger\) p<0.05 significant change after 12 months within the group.

*\(p<0.05\) significant difference in change after 12 months between the groups (treatment effect).
Low CCQ scores indicate high quality of life. A negative treatment effect signifies a bigger improvement after 12 months for the NIV group compared to standard treatment.
Supplementary file Table S4: Changes in the Maugeri Respiratory Questionnaire-28 (MRF-28) subdomains

<table>
<thead>
<tr>
<th></th>
<th>ITT Baseline</th>
<th>n</th>
<th>Completers Baseline</th>
<th>n</th>
<th>Completers 12 months</th>
<th>n</th>
<th>Change over 1 year</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MRF-28-Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>60.9 ± 23.6</td>
<td>99</td>
<td>58.3 ± 24.3</td>
<td>50</td>
<td>51.0 ± 24.8</td>
<td>50</td>
<td>-7.3 (-12.5; -2.1)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>60.3 ± 23.9</td>
<td>90</td>
<td>55.3 ± 24.2</td>
<td>51</td>
<td>49.4 ± 25.0</td>
<td>51</td>
<td>-5.8 (-10.8; -0.8)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daily activities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>62.3 ± 28.4</td>
<td>99</td>
<td>62.0 ± 29.9</td>
<td>50</td>
<td>54.5 ± 35.4</td>
<td>50</td>
<td>-7.5 (-15.09; 0.03)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>61.7 ± 30.5</td>
<td>90</td>
<td>55.6 ± 30.7</td>
<td>51</td>
<td>46.3 ± 29.2</td>
<td>51</td>
<td>-9.3 (-16.1; -2.4)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cognition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>48.5 ± 41.0</td>
<td>99</td>
<td>44.5 ± 40.8</td>
<td>50</td>
<td>33.7 ± 36.3</td>
<td>50</td>
<td>-10.8 (-22.5; 0.8)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>43.3 ± 35.9</td>
<td>90</td>
<td>39.7 ± 35.4</td>
<td>51</td>
<td>36.3 ± 35.5</td>
<td>51</td>
<td>-3.4 (-12.7; 5.8)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invalidity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>74.2 ± 31.2</td>
<td>99</td>
<td>70.6 ± 34.0</td>
<td>50</td>
<td>69.5 ± 34.8</td>
<td>50</td>
<td>-1.1 (-9.4; 7.2)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>68.7 ± 33.5</td>
<td>90</td>
<td>59.2 ± 37.7</td>
<td>51</td>
<td>57.3 ± 39.4</td>
<td>51</td>
<td>-2.0 (-10.0; 6.1)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data presented as means (± standard deviation) and mean change (95% confidence intervals).

ITT, intention-to-treat; MRF-28, Maugeri Respiratory Questionnaire-28; n, numbers for analysis;

NIV, noninvasive positive pressure ventilation.

¶ p<0.05 significant change after 12 months within the group.

*p<0.05 significant difference in change after 12 months between the groups (treatment effect).

Low MRF-28 scores indicate high quality of life. A negative treatment effect signifies a bigger improvement after 12 months for the NIV group compared to standard treatment.
Supplementary file Table S5: Changes in the Clinical Respiratory Questionnaire (CRQ) sub domains

<table>
<thead>
<tr>
<th></th>
<th>ITT Baseline</th>
<th>n</th>
<th>Completers Baseline</th>
<th>N</th>
<th>Completers 12 months</th>
<th>n</th>
<th>Change score 12 months</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRQ-Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>3.5 ± 1.1</td>
<td>100</td>
<td>3.5 ± 1.1</td>
<td>50</td>
<td>4.2 ± 1.2</td>
<td>50</td>
<td>0.7 (0.4; 1.1) $^*$</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>3.6 ± 1.1</td>
<td>89</td>
<td>3.6 ± 1.1</td>
<td>50</td>
<td>4.4 ± 1.2</td>
<td>50</td>
<td>0.7 (0.4; 1.0) $^*$</td>
<td>50</td>
</tr>
<tr>
<td>Treatment effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnoea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>3.0 ± 2.7</td>
<td>100</td>
<td>3.1 ± 1.6</td>
<td>49</td>
<td>3.5 ± 1.7</td>
<td>49</td>
<td>0.4 (0.03; 0.8) $^*$</td>
<td>49</td>
</tr>
<tr>
<td>Controls</td>
<td>3.25 ± 1.4</td>
<td>85</td>
<td>3.4 ± 1.5</td>
<td>46</td>
<td>3.9 ± 1.5</td>
<td>46</td>
<td>0.5 (-0.002; 0.9)</td>
<td>46</td>
</tr>
<tr>
<td>Treatment effect</td>
<td>-0.02 (-0.6; 0.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>2.70 ±1.3</td>
<td>100</td>
<td>2.8 ± 1.3</td>
<td>50</td>
<td>3.8 ± 1.5</td>
<td>50</td>
<td>1.0 (0.5; 1.4) $^*$</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>2.62 ±1.2</td>
<td>89</td>
<td>2.5 ± 1.0</td>
<td>50</td>
<td>3.7 ± 1.3</td>
<td>50</td>
<td>1.1 (0.8; 1.5) $^*$</td>
<td>50</td>
</tr>
<tr>
<td>Treatment effect</td>
<td>-0.2 (-0.7; 0.4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emotion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>3.93 ±1.3</td>
<td>100</td>
<td>3.9 ± 1.3</td>
<td>46</td>
<td>4.6 ± 1.3</td>
<td>50</td>
<td>0.7 (0.3; 1.1) $^*$</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>4.09 ±1.2</td>
<td>89</td>
<td>4.1 ± 1.3</td>
<td>50</td>
<td>4.7 ± 1.4</td>
<td>50</td>
<td>0.6 (0.3; 0.9) $^*$</td>
<td>50</td>
</tr>
<tr>
<td>Treatment effect</td>
<td>0.1 (-0.4; 0.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mastery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>3.86 ±1.4</td>
<td>100</td>
<td>3.8 ± 1.4</td>
<td>50</td>
<td>4.6 ± 1.4</td>
<td>50</td>
<td>0.8 (0.4; 1.2) $^*$</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>4.01 ±1.4</td>
<td>89</td>
<td>4.0 ± 1.4</td>
<td>50</td>
<td>5.0 ± 1.4</td>
<td>50</td>
<td>0.9 (0.5; 1.3) $^*$</td>
<td>50</td>
</tr>
<tr>
<td>Treatment effect</td>
<td>-0.1 (-0.7; 0.4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data presented as means (± standard deviation) and mean change (95% confidence intervals).
CRQ, Clinical Respiratory Questionnaire; ITT, intention-to-treat; n, numbers for analysis; NIV, noninvasive positive pressure ventilation.

$^*$ p<0.05 significant change after 12 months within the group.

* p<0.05 significant difference in change after 12 months between the groups (treatment effect).

High CRQ scores indicate high quality of life. A positive treatment effect signifies a bigger improvement after 12 months for the NIV group compared to standard treatment.
Table S6: Changes in the Severe Respiratory Insufficiency questionnaire (SRI) sub domains

<table>
<thead>
<tr>
<th></th>
<th>ITT Baseline</th>
<th>n</th>
<th>Completers Baseline</th>
<th>N</th>
<th>Completers 12 months</th>
<th>n</th>
<th>Change score 12 months</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SRI-Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>48.1 ± 15.0</td>
<td>100</td>
<td>47.9 ± 15.1</td>
<td>50</td>
<td>55.0 ± 15.4</td>
<td>50</td>
<td>7.0 (3.4; 10.7)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>51.3 ± 15.9</td>
<td>90</td>
<td>53.6 ± 16.9</td>
<td>51</td>
<td>55.8 ± 16.3</td>
<td>51</td>
<td>2.2 (-1.2; 5.6)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.8 (-0.1; 9.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory complaints</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>47.9 ± 19.6</td>
<td>100</td>
<td>48.9 ± 21.2</td>
<td>50</td>
<td>55.6 ± 19.4</td>
<td>50</td>
<td>6.7 (2.1; 11.2)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>44.0 ± 18.6</td>
<td>90</td>
<td>45.7 ± 18.5</td>
<td>51</td>
<td>54.3 ± 16.7</td>
<td>51</td>
<td>8.6 (3.8; 13.5)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-2.0 (-8.6; 4.6)</td>
<td></td>
</tr>
<tr>
<td><strong>Physical functioning</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>32.0 ± 18.5</td>
<td>100</td>
<td>32.7 ± 21.6</td>
<td>50</td>
<td>36.5 ± 21.6</td>
<td>50</td>
<td>3.8 (-1.4; 9.0)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>32.5 ± 21.9</td>
<td>90</td>
<td>37.3 ± 21.4</td>
<td>51</td>
<td>41.3 ± 21.6</td>
<td>51</td>
<td>4.1 (-1.7; 9.9)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.3 (-8.0; 7.4)</td>
<td></td>
</tr>
<tr>
<td><strong>Attendant symp+sleep</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>57.1 ± 18.4</td>
<td>100</td>
<td>54.4 ± 17.9</td>
<td>50</td>
<td>64.8 ± 18.0</td>
<td>50</td>
<td>10.4 (5.3; 15.5)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>58.6 ± 20.0</td>
<td>90</td>
<td>59.9 ± 22.3</td>
<td>51</td>
<td>61.7 ± 18.4</td>
<td>51</td>
<td>1.7 (-2.9; 6.4)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8.7 (1.9; 15.4)</td>
<td></td>
</tr>
<tr>
<td><strong>Social relationships</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>58.3 ± 17.1</td>
<td>100</td>
<td>56.3 ± 14.0</td>
<td>50</td>
<td>60.9 ± 18.9</td>
<td>50</td>
<td>4.6 (-0.2; 9.4)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>66.5 ± 17.1</td>
<td>90</td>
<td>68.2 ± 17.3</td>
<td>51</td>
<td>64.3 ± 17.4</td>
<td>51</td>
<td>-3.9 (-7.7; 0.03)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8.4 (2.4; 14.5)</td>
<td></td>
</tr>
<tr>
<td><strong>Anxiety</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>46.2 ± 22.5</td>
<td>100</td>
<td>47.0 ± 24.6</td>
<td>50</td>
<td>59.8 ± 22.1</td>
<td>52</td>
<td>12.8 (7.1; 18.5)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>50.4 ± 25.4</td>
<td>90</td>
<td>52.6 ± 26.3</td>
<td>51</td>
<td>58.2 ± 23.0</td>
<td>51</td>
<td>5.7 (0.6; 10.7)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7.1 (-0.4; 14.6)</td>
<td></td>
</tr>
<tr>
<td><strong>Well-being</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>52.6 ± 20.1</td>
<td>100</td>
<td>52.2 ± 19.1</td>
<td>50</td>
<td>58.1 ± 22.9</td>
<td>50</td>
<td>5.9 (0.7; 11.1)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>59.3 ± 20.4</td>
<td>90</td>
<td>60.4 ± 22.1</td>
<td>51</td>
<td>60.3 ± 21.3</td>
<td>51</td>
<td>-0.1 (-4.7; 4.4)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.0 (-0.8; 12.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Social functioning</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIV</td>
<td>43.1 ± 40.6</td>
<td>100</td>
<td>44.0 ± 19.4</td>
<td>50</td>
<td>49.1 ±20.1</td>
<td>50</td>
<td>5.1 (-0.2; 10.4)</td>
<td>50</td>
</tr>
<tr>
<td>Controls</td>
<td>48.0 ± 20.4</td>
<td>90</td>
<td>51.4 ± 21.6</td>
<td>51</td>
<td>50.7 ± 23.1</td>
<td>51</td>
<td>-0.8 (-5.9; 4.4)</td>
<td>51</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.9 (-1.4; 13.2)</td>
<td></td>
</tr>
</tbody>
</table>

Data presented as means (± standard deviation) and mean change (95% confidence intervals).

Attendant symp+sleep, attendant symptoms and sleep sub domain; ITT, intention-to-treat; n, numbers for analysis; NIV, noninvasive positive pressure ventilation; SRI, Severe Respiratory Insufficiency questionnaire.

¶ p<0.05 significant change after 12 months within the group.

* p<0.05 significant difference in change after 12 months between the groups (treatment effect).

High SRI scores indicate high quality of life. A positive treatment effect signifies a bigger improvement after 12 months for the NIV group compared to standard treatment.
Supplementary file Table S7: Changes in the Groningen Activity and Restriction Scale (GARS), Hospital Anxiety and Depression Scale (HADS) and Medical Research Council (MRC) sub domains

<table>
<thead>
<tr>
<th></th>
<th>ITT</th>
<th>n Baseline</th>
<th>Completers</th>
<th>n Baseline</th>
<th>Completers</th>
<th>n 12 months</th>
<th>Change score</th>
<th>n 12 months</th>
<th>n 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GARS-Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NIV</td>
<td>36.7 ± 7.5</td>
<td>100</td>
<td>36.3 ± 8.3</td>
<td>50</td>
<td>34.6 ± 9.4</td>
<td>-1.6 (-3.3; 0.1)</td>
<td>50</td>
<td>-1.6 (-3.3; 0.1)</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>36.8 ± 8.5</td>
<td>90</td>
<td>34.7 ± 1.2</td>
<td>51</td>
<td>32.7 ± 8.2</td>
<td>-2.0 (-4.1; 0.1)</td>
<td>51</td>
<td>-2.0 (-4.1; 0.1)</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>0.4 (-2.3; 3.0)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HADS-Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NIV</td>
<td>15.9 ± 9.2</td>
<td>98</td>
<td>15.6 ± 8.5</td>
<td>48</td>
<td>13.9 ± 8.8</td>
<td>-1.7 (-4.0; 0.6)</td>
<td>48</td>
<td>-1.7 (-4.0; 0.6)</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>14.5 ± 8.8</td>
<td>87</td>
<td>13.1 ± 9.1</td>
<td>50</td>
<td>12.7 ± 9.3</td>
<td>-0.4 (-2.2; 1.3)</td>
<td>50</td>
<td>-0.4 (-2.2; 1.3)</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>-1.3 (-4.1; 1.6)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HADS anxiety</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NIV</td>
<td>7.8 ± 5.0</td>
<td>99</td>
<td>7.9 ± 4.7</td>
<td>49</td>
<td>6.6 ± 4.7</td>
<td>-1.3 (-2.3; -0.2)</td>
<td>49</td>
<td>-1.3 (-2.3; -0.2)</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>7.3 ± 4.6</td>
<td>88</td>
<td>6.8 ± 4.8</td>
<td>51</td>
<td>5.9 ± 4.8</td>
<td>-0.9 (-1.8; 0.02)</td>
<td>51</td>
<td>-0.9 (-1.8; 0.02)</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>-0.4 (-1.8; 1.0)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HADS depression</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NIV</td>
<td>8.1 ± 4.9</td>
<td>99</td>
<td>7.5 ± 4.8</td>
<td>50</td>
<td>7.1 ± 4.6</td>
<td>-0.4 (-1.7; 0.9)</td>
<td>50</td>
<td>-0.4 (-1.7; 0.9)</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>7.1 ± 4.7</td>
<td>87</td>
<td>6.3 ± 4.7</td>
<td>50</td>
<td>6.7 ± 5.1</td>
<td>0.4 (-0.6; 1.5)</td>
<td>50</td>
<td>0.4 (-0.6; 1.5)</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>-0.8 (0.8; -2.5)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MRC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NIV</td>
<td>3.9 ± 1.0</td>
<td>98</td>
<td>3.8 ± 1.4</td>
<td>49</td>
<td>3.5 ± 1.4</td>
<td>-0.4 (-0.7; -0.02)</td>
<td>49</td>
<td>-0.4 (-0.7; -0.02)</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>3.8 ± 1.0</td>
<td>90</td>
<td>3.6 ± 1.1</td>
<td>51</td>
<td>3.3 ± 1.2</td>
<td>-0.3 (-0.7; 0.08)</td>
<td>51</td>
<td>-0.3 (-0.7; 0.08)</td>
</tr>
<tr>
<td><strong>Treatment effect</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>-0.05 (-0.6; 0.5)</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data presented as means (± standard deviation) and mean change (95% confidence intervals).

GARS, Groninger Activity Restriction Scale; HADS, Hospital Anxiety and Depression Scale; ITT, intention-to-treat; n, numbers for analysis; NIV, noninvasive positive pressure ventilation; MRC, Medical Research Council dyspnoea scale.

* p<0.05 significant difference in change after 12 months between the groups (treatment effect).

Low GARS scores indicate better daily activity levels. Low HADS scores indicate better mood state. Lower MRC scores represent less dyspnoea. A negative treatment effect signifies a bigger improvement after 12 months for the NIV group compared to standard treatment.
REFERENCES


